Center-Authored Papers

Filters: First Letter Of Keyword is P  [Clear All Filters]
A B C D E F G H I J K L M N O [P] Q R S T U V W X Y Z   [Show ALL]
Pyrrolidines
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J et al..  2010.  Lasofoxifene in postmenopausal women with osteoporosis.. The New England journal of medicine. 362(8):686-96. Abstract
Ensrud K, LaCroix AZ, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R et al..  2010.  Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.. Circulation. 122(17):1716-24. Abstract
Pyrroles
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG.  2010.  Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(21):5260-8. Abstract
Hartwell LH, MAGASANIK B.  1964.  THE MECHANISM OF HISTIDASE INDUCTION AND FORMATION IN BACILLUS SUBTILIS.. Journal of molecular biology. 10:105-19.
Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.  2008.  An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.. PharmacoEconomics. 26(4):329-39. Abstract
Pyrophosphatases
Fishburn J, Hahn S.  2012.  Architecture of the yeast RNA polymerase II open complex and regulation of activity by TFIIF.. Molecular and cellular biology. 32(1):25. Abstract
Pyrimidines
Radich JP.  2012.  Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.. Cancer. 118(2):300-11. Abstract
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS.  2008.  Imatinib inhibition of fludarabine uptake in T-lymphocytes.. Cancer chemotherapy and pharmacology. 62(4):735-9. Abstract
Mendiratta P, Mostaghel EA, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson PS, Febbo PG.  2009.  Genomic strategy for targeting therapy in castration-resistant prostate cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(12):2022-9. Abstract
Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP et al..  2011.  SHP1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.. Blood. 118(13):3634-44. Abstract
Müller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L et al..  2009.  Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.. Blood. 114(24):4944-53. Abstract
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F et al..  2013.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood. 122(6):872-84. Abstract
Travi G, Pergam SA, Xie H, Carpenter PA, Kiem H-P, Corey L, Boeckh MJ.  2009.  The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 49(11):e120-3. Abstract
Hartwell LH.  1970.  Biochemical genetics of yeast.. Annual review of genetics. 4:373-96.
Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT, Cortes J.  2013.  Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(7):1884-93. Abstract
Radich JP.  2010.  Stem cell transplant for chronic myeloid leukemia in the imatinib era.. Seminars in hematology. 47(4):354-61. Abstract
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG et al..  2010.  Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).. Blood. 116(19):3758-65. Abstract
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP et al..  2008.  Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.. Blood. 112(8):3500-7. Abstract
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract